| Date | Title | Description |
| 14.07.2026 | Американская Vertex Pharmaceuticals покупает биофармацевтическую Crinetics за $10 млрд | Американская биотехнологическая компания Vertex Pharmaceuticals, специализирующаяся на разработке инновационных препаратов для лечения тяжелых и редких заболеваний, договорилась о приобретении американской биофармацевтической компании Crine... |
| 08.07.2026 | Vertex купит разработчика препаратов от эндокринных заболеваний за $10 млрд | Vertex купит разработчика препаратов от эндокринных заболеваний за $10 млрд Сделка станет одной из крупнейших для американской компании
Американская биотехнологическая компания Vertex Pharmaceuticals договорилась о покупке Crinetics Pharmac... |
| 07.07.2026 | Stocks making the biggest moves midday: SpaceX, GE Vernova, Crinetics Pharmaceuticals, Rivian & more | - |
| 07.07.2026 | AI stocks sink and drag markets lower worldwide | Getting your Trinity Audio player ready...
By STAN CHOE, AP Business Writer
NEW YORK (AP) — The roller-coaster ride for AI stocks snapped back down on Tuesday and dragged Wall Street lower.
The S&P 500 fell 0.4% even though the majority... |
| 07.07.2026 | Stocks making the biggest moves premarket: Fiserv, Crinetics Pharmaceuticals, Micron & more | - |
| 06.07.2026 | Daily Stock Market Live
Nasdaq futures fall as chip stocks struggle: Live updates | Nasdaq-100 futures fell Tuesday, weighed down by a decline in chip stocks as investors once again appear to rotate out of names tied to artificial intelligence.
Futures tied to the tech-heavy index were down 0.9%, while S&P 500 futures ... |
| 15.06.2026 | CAH Drug Atumelnant Cut Androgens 67% While Ending Decades of Steroid Overload | By John Bright
Published: Jun 15 2026, 14:41 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 15.06.2026 | Oral Acromegaly Pill PALSONIFY Sustains Two-Year IGF-1 Control in New ENDO Data | By Chase Fiorini
Published: Jun 15 2026, 10:12 AM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 07.10.2024 | Did this congressman benefit from a stock buy just before FDA approval? | On October 3, Representative Josh Gottheimer of New Jersey’s 5th district disclosed a September 25 investment in Crinetics Pharmaceuticals (NASDAQ: CRNX), a mid-cap stock that no U.S. politician had previously traded.
At that time, the CRNX... |
| 08.08.2024 | Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update | Paltusotine NDA Submission in Acromegaly On Track for 2024
Topline Results from Phase 2 Studies of Atumelnant in Congenital Adrenal Hyperplasia and Additional Data for Phase 2 for ACTH-Dependent Cushing’s Syndrome Expected by End of 2024
Ma... |
| 12.03.2024 | Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome | - |
| 12.03.2024 | Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome | Paltusotine Treatment Demonstrated Rapid and Sustained Reductions in Frequency and Severity of Flushing Episodes and Bowel Movements
Paltusotine was Generally Well-Tolerated and Showed an Overall PK Profile Consistent with Prior Studies
Res... |
| 11.03.2024 | Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, March 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to pu... |
| 11.03.2024 | Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | - |
| 28.02.2024 | Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | Phase 3 PATHFNDR-2 Study Topline Results Expected in March 2024; Pending Results, NDA Submission in Acromegaly Anticipated 2H 2024
Phase 2 Study of Paltusotine in Carcinoid Syndrome Full Topline Results Expected 1H 2024
Announced a $350 Mil... |
| 17.08.2023 | Startup is developing a pill intended to help large dogs live longer | San Francisco-based Loyal is working on a new drug it hopes will help large dogs live healthier, longer lives.
Driving the news: Loyal recently partnered with pharmaceutical company Crinetics to get exclusive veterinary access to its compou... |
| 04.05.2023 | Pioneering Pharmaceutical Company Supports Next Generation with Unique Employee Benefit | TOOTRiS Child Care On-Demand
TOOTRiS Child Care On-Demand and Crinetics Pharmaceuticals partner to provide child care benefits to new and current employees
SAN DIEGO, CALIFORNIA, UNITED STATES, May 4, 2023/EINPresswire.com/ -- As 1 in 3 wor... |
| 12.01.2022 | Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference | - Phase 1 multiple ascending dose data for CRN04894 and CRN04777 expected in 1Q 2022 –
- Initiation of patient dosing in a Phase 2 trial of paltusotine in carcinoid syndrome associated with neuroendocrine tumors expected in 2022 -
- Initiat... |
| 28.10.2021 | Radionetics Oncology Launches with $30M Investment | Photo Courtesy of Crinetics San Diego-based Crinetics Pharmaceuticals focuses on discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Radionetics Oncology, a pharmaceutical c... |
| 25.10.2021 | Crinetics Pharmaceuticals : Announces Closing of Public Offering of Common Stock | SAN DIEGO - October 25, 2021 - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocri... |
| 06.05.2021 | CRINETICS PHARMACEUTICALS, INC.
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update | Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021
Phase 1 data for CRN04894 and CRN04777 expected in mid-2021
SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage... |
| 30.03.2021 | CRINETICS PHARMACEUTICALS, INC.
Crinetics Pharmaceuticals : Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results | Advancing paltusotine into a Phase 3 program for acromegaly following an FDA meeting
Phase 1 clinical proof-of-concept data for CRN04894 and CRN04777 expected in 1H 2021 and mid-2021, respectively
Management hosting webcast and conference c... |
| 10.07.2018 | Rare endocrine disease biotech Crinetics Pharmaceuticals sets terms for $80 million IPO | - |
| 14.03.2018 | Crinetics raises $63.5M for oral acromegaly therapy | San Diego biotech Crinetics has raised $63.5 million in new funding to help take its oral alternative to injected drugs for acromegaly through a proof-of-concept trial.
The Series B comes two years after Crinetics raised $40 million in firs... |
| 13.03.2018 | CRINETICS PHARMACEUTICALS COMPLETES $63.5 MILLION SERIES B FINANCING | - |
| 13.07.2017 | CRINETICS PHARMACEUTICALS AWARDED $2.8 MILLION SBIR GRANT TO SUPPORT DEVELOPMENT OF ACROMEGALY DRUG CANDIDATE CRN00808 | - |
| 02.11.2015 | Crinetics Pharmaceuticals Inks $40M Series A |
SAN DIEGO, CA, Innovative therapeutics company focused on specialty endocrine disorders, announced today the completion of a $40 million series A financing.
>> Click here for more funding data on Crinetics Pharmaceuticals
>>... |
| 02.11.2015 | Daily funding roundup - November 2, 2015 | Handy raised $50M; Clearsky Data scored $27M; Confer secured $17M
Twigly, a Gurgaon, India-based curated food marketplace, raised $200,000 in seed funding. Backers included Tracxn Labs and angels Amit Gupta, Aloke Bajpai, Ashish Kumar, and ... |
| 02.11.2015 | Crinetics Pharmaceuticals Completes $40M Series A Financing | Crinetics Pharmaceuticals, a San Diego, California-based therapeutics company focused on specialty endocrine disorders, completed a $40m Series A financing.
The round was led by 5AM Ventures, Versant Ventures, and Vivo Capital. In conjuncti... |
| 02.11.2015 | CRINETICS PHARMACEUTICALS COMPLETES $40 MILLION SERIES A FINANCING | - |
| 02.11.2015 |
Crinetics Pharmaceuticals Finds $40M
| San Diego-based Crinetics Pharmaceuticals, a company developing treatments for endocrine disorders, said this morning that it has raised $40M in a Series A funding. The funding was led by 5AM Ventures, Versant Ventures, and Vivo Capital. As... |
| - | - | Crinetics won FDA approval for Palsonify to treat a rare condition that occurs when the pituitary gland produces too much growth …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choos... |
